Medtec China 2018 is taking place on September 26–28 in Shanghai China. This year the scale of the show will grow by 10% reaching a new height since 2015; it is now at a scale making utilization of an entire hall possible to hold the show.
Measures aimed at addressing rising healthcare and health insurance costs in Singapore have been announced.
The use of Internet of Things in Healthcare is going to be revolutionary in the next years. IoT is now pretty much in everything we touch in our modern lives, technology is now a common denominator in most of everybody’s life.
AMRA has signed a new agreement to integrate its body composition analysis into Siemens Healthineers Digital Ecosystem for increased access to healthcare professionals and researchers. Intended to aid in disease prediction, AMRA’s body composition analysis is an automated method designed to convert a six-minute whole body MRI scan into 3D-volumetric fat and muscle measurements.
The medical industry is constantly changing. New medical devices are created at an alarming rate. It’s crucial that the companies creating these devices are able to keep up with the latest technology. Medical devices perform a wide variety of extremely important jobs. Any malfunction or failure can be disastrous.
New US research has found that smoking while pregnant could be even worse for children with asthma than exposing them to secondhand smoke in childhood.
Antimicrobial resistance is a global threat to human health. Novo Holdings today announces the launch of an impact fund commissioned by the Novo Nordisk Foundation with a total budget of USD 165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance.
Four health systems — Intermountain Healthcare, Ascension, SSM Health and Trinity Health — and the U.S. Department of Veterans Affairs will launch a nonprofit generic drug company.
AstraZeneca today announced that the European Medicines Agency has accepted the Marketing Authorisation Variation forForxiga (dapagliflozin), a selective SGLT-2 inhibitor, for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D).
Vividion to receive $101 million in upfront payment, including equity investment Collaboration utilizes Vividion's unique proteome-wide ligand and target discovery platform
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.